Severity of oEsophageal Anastomotic Leak in patients after oesophagectomy: the SEAL score Open Access

Abstract

Background

Anastomotic leak (AL) is a common but severe complication after oesophagectomy. It is unknown how to determine the severity of AL objectively at diagnosis. Determining leak severity may guide treatment decisions and improve future research. This study aimed to identify leak-related prognostic factors for mortality, and to develop a Severity of oEsophageal Anastomotic Leak (SEAL) score.

Methods

This international, retrospective cohort study in 71 centres worldwide included patients with AL after oesophagectomy between 2011 and 2019. The primary endpoint was 90-day mortality. Leak-related prognostic factors were identified after adjusting for confounders and were included in multivariable logistic regression to develop the SEAL score. Four classes of leak severity (mild, moderate, severe, and critical) were defined based on the risk of 90-day mortality, and the score was validated internally.

Results

Some 1509 patients with AL were included and the 90-day mortality rate was 11.7 per cent. Twelve leak-related prognostic factors were included in the SEAL score. The score showed good calibration and discrimination (c-index 0.77, 95 per cent c.i. 0.73 to 0.81). Higher classes of leak severity graded by the SEAL score were associated with a significant increase in duration of ICU stay, healing time, Comprehensive Complication Index score, and Esophagectomy Complications Consensus Group classification.

Conclusion

The SEAL score grades leak severity into four classes by combining 12 leak-related predictors and can be used to the assess severity of AL after oesophagectomy.

Introduction

Anastomotic leak (AL) is a major complication after oesophagectomy, and leak rates of between 10 and 20 per cent have been reported^1–3. Annually, an estimated 20 000 patients worldwide may develop AL after oesophagectomy^1,4–6. AL is associated with increased postoperative morbidity, high postoperative mortality rates, prolonged hospital admission, and increased hospital costs^1,7–10. In addition, it has been shown to decrease long-term quality of life and oncological survival^11–13.

The clinical presentation of patients with AL is diverse and its impact ranges widely. Patients may or may not present with signs of systemic infection, contaminated fluid collections, and/or conduit necrosis. Currently, it is not known how to determine the severity of AL at diagnosis, but a better understanding of its severity may guide treatment strategies. Furthermore, a tool to assess leak severity could improve the comparability of future research and may be used to correct for leak severity. Therefore, a tool to assess the severity of AL at diagnosis is needed.

AL is currently classified according to the definition of the Esophagectomy Complications Consensus Group (ECCG)¹⁴. Aimed at improving benchmarking and consistent reporting of research outcomes, this classification is based on the invasiveness of the leak treatment (conservative, radiological or endoscopic intervention, and surgical intervention). However, this system does not reflect the severity of AL in terms of outcome. In addition, as the score is determined in hindsight by the treatment performed, this classification cannot guide treatment decisions in clinical practice. The ultimate measure of leak severity is the risk of death. AL severity should be determined by leak-related parameters that are available at diagnosis to enable adequate decision-making based on AL severity. However, only small and heterogeneous cohort studies^1,9,15–19 have investigated which leak-related factors are associated with leak severity, and no comprehensive severity score has been developed.

The aims of this study were to identify leak-related prognostic factors for 90-day mortality in patients with AL after oesophagectomy with gastric tube reconstruction for cancer, and to develop a Severity of oEsophageal Anastomotic Leak (SEAL) score to classify the severity of AL at diagnosis in these patients.

Methods

Study design

TENTACLE—Esophagus (TreatmENT of AnastomotiC Leakage after Esophagectomy) is an international multicentre retrospective cohort study. Centres performing oesophageal cancer surgery were invited to participate and the study was performed in collaboration with the Dutch Upper Gastrointestinal Cancer Audit, Oesophago-Gastric Anastomosis Audit, and European Minimally Invasive Oesophagectomy Think Tank initiative. Participation was allowed irrespective of geography and patient volume. Seventy-one centres from 20 different countries participated in this study (Table S1).

The study protocol was approved by the institutional review board of Radboud University Medical Centre, and by local ethics committees of participating centres if additional approval was needed. The need for individual informed consent was waived owing to the retrospective study design and anonymous data collection. This study was performed according to TRIPOD guidelines²⁰. The TENTACLE—Esophagus study is registered in the Clinical Trials registry (NCT03829098) and the full study protocol is accessible at https://www.tentaclestudy.com.

Population

Adults who developed AL after oesophagectomy with gastric tube reconstruction for resectable cancer of the oesophagus or gastro-oesophageal junction (cT1–4a N0–3 M0) between January 2011 and June 2019 were included consecutively. AL was defined as a ‘full-thickness gastrointestinal defect involving oesophagus, anastomosis, staple line or conduit, irrespective of presentation or method of identification’¹⁴. Patients who were diagnosed with AL after death or who underwent an emergency oesophagectomy or oesophagectomy for benign disease were excluded.

Data collection, verification, and quality validation

Data were collected by local investigators at each participating centre and recorded in an online database (www.castoredc.com). Data were pseudoanonymized and traceable patient data were stored locally.

To ensure robustness of data and to minimize the risk of incomplete patient inclusion, data verification and data quality validation were undertaken (Appendix S1). For data verification, an algorithm was developed to screen all data fields for inconsistent entries, typographical errors, and missing values. Data quality validation was performed by independent local validators to assess case ascertainment and data accuracy. Case ascertainment was assessed by comparing a centre's number of included patients with the expected number of leaks based on the centre's annual resection rate and expected minimum leak rate of 5 per cent. Data accuracy was assessed by retrieving 15 key parameters from medical records and comparing these with study data.

Outcome measures

The primary outcome was 90-day mortality, defined as death from any cause within 90 days after oesophagectomy. Mortality was used as a proxy for leak severity, and 90-day mortality was chosen because it reflects most complication-related deaths without including deaths unrelated to AL (such as early recurrence)^21,22. Secondary outcomes were used to assess the clinical relevance of the SEAL score and included in-hospital, 30-day, and 180-day mortality, duration of ICU and hospital stay, time to leak healing (confirmed by imaging or clinically if patients were put on (at least) a non-clear liquid diet), Comprehensive Complication Index (CCI) score, and ECCG classification. The CCI represents the severity of all complications, ranging from 0 (no complications) to 100 (death)²³. The ECCG classification consists of three leak types: type I, AL requiring medical, dietary or no therapy; type II, AL requiring reintervention but not surgical reintervention; and type III, requiring surgical therapy¹⁴.

Prognostic factors and predictors

Potential leak-related prognostic factors for 90-day mortality and predictors for the SEAL score were selected based on the literature and expert opinion. Although preoperative parameters (such as age or co-morbidity) may affect outcomes, these factors do not reflect the severity of the leak itself, and so were not included as predictors in the SEAL score. Grading of AL severity may be considered analogously to grading of tumours; although parameters such as age or co-morbidity affect outcomes and are often taken into account when making treatment decisions, the tumour itself is graded by its size and extent of dissemination²⁴. Similarly, in the SEAL score, the leak itself is graded by leak-related parameters at diagnosis and preoperative parameters were not included in this score (Table 1).

Statistical analysis

Multiple imputation using chained equations was used to reduce bias in results owing to missing data. Additional information on (handling of) missing data is presented in Appendix S2 and Table S2²⁵.

Prognostic factors for 90-day mortality were identified by assessing the effect of individual parameters on 90-day mortality. Crude and adjusted ORs and 95 per cent confidence intervals were estimated using univariable and multivariable logistic regression analyses. Confounding variables used for adjustment of each potential prognostic factor were selected using a directed acyclic graph (DAG) (Appendix S3 and Fig. S1)²⁶.

The SEAL score was developed using multivariable logistic regression to determine the risk of 90-day mortality (Appendix S4). Leak-related parameters identified as prognostic factors after adjustment for confounders were included as predictors for the SEAL score. Predictors for the SEAL score were not selected using backwards selection as described in the online protocol, but were selected using the DAG approach as inclusion of causal predictors may benefit model performance^27,28. The model was validated internally using bootstrapping techniques (500 replicates). Model coefficients were adjusted for the shrinkage factor found during bootstrapping. After internal validation, the model performance was re-evaluated. Model performance was assessed in terms of discrimination expressed as concordance index (c-index) and calibration using a calibration plot²⁹. A sensitivity analysis was undertaken, assessing model performance in subgroups based on geographical location.

The SEAL score was divided into four classes of AL severity: mild, moderate, severe, and critical. Class cut-off values were predefined by the study group based on clinical judgement of AL severity in relation to the risk of 90-day mortality: mild, less than 5 per cent; moderate, ≥5–<15 per cent; severe, ≥15–<25 per cent; and critical, at least 25 per cent predicted risk of 90-day mortality. Secondary outcomes were compared between different classes of leak severity using the χ² test for ordinal outcomes and one-way ANOVA for continuous outcomes. P < 0.050 was considered statistically significant. All statistical analyses were performed in each imputed data set and pooled subsequently using R version 3.6.2 with packages rms and mice (R Foundation for Statistical Computing, Vienna, Austria)³⁰.

Results

Preoperative characteristics

A total of 1514 patients with AL were included in the database. Five patients were excluded owing to locally advanced disease (cT4b) (3 patients), oesophagojejunal reconstruction (1), and post-mortem diagnosis of AL (1). Preoperative characteristics of 1509 patients included in the analysis are shown in Table 2.

Data quality validation

Of the 71 participating centres, 9 (13 per cent) included a smaller sample than expected. The patient screening procedures at these centres were reviewed and were found appropriate in 8 centres. One centre, which included 3 patients, rescreened their records and included 3 additional patients. Of 1514 records, 182 (12.0 per cent) were validated for data accuracy assessment and overall data accuracy was 96.5 per cent (Appendix S1).

Leak-related parameters at diagnosis of anastomotic leak

The median postoperative day (POD) of diagnosis (defined as confirmation of AL by clinical, imaging or other assessment) was day 8 (i.q.r. 5–11) days after oesophagectomy. Most patients (56.3 per cent) had undergone transthoracic oesophagectomy with intrathoracic anastomosis; 27.0 per cent had undergone transthoracic oesophagectomy with cervical anastomosis, and 16.0 per cent transhiatal oesophagectomy. At diagnosis of AL, 57.1 per cent of patients were on the surgical ward and 36.0 per cent in a high-care department. AL was most often diagnosed by CT, drain fluids, oesophagography, and endoscopy (49.2, 17.2, 13.6, and 12.1 per cent respectively). Some 54.7 per cent of patients had intrathoracic fluid collections (i.e. drained or undrained, mediastinal or pleural), 16.3 per cent had cervical fluid collections, and 20.6 per cent had no fluid collections. A defect circumference of 25 per cent or more was observed in 12.8 per cent of patients. Overall conduit ischaemia/necrosis was found in 9.8 per cent (Table 3).

Outcomes

The 90-day mortality rate was 11.7 per cent (176 deaths), and 30-day, 180-day and in-hospital mortality rates were 5.2, 15.9, and 10.7 per cent respectively. The median duration of hospital stay was 30 (i.q.r. 20–49) days and of ICU stay was 6 (2–15) days. The anastomotic defect healed in 1270 patients (84.2 per cent) and the median time to healing was 26 (i.q.r. 13–46) days. The median CCI score was 44 (i.q.r. 31–64). Of all patients, 27.3 per cent had an ECCG type I leak, 36.8 per cent a type II leak, and 36.0 per cent a type III leak.

Prognostic factors for mortality

Crude and adjusted ORs for possible prognostic factors for 90-day mortality are presented in Table S3. The following leak-related parameters at diagnosis of AL were identified as prognostic factors: early or late diagnosis of AL (before POD 5 and after POD 11), organ failure (respiratory failure, haemodynamic failure, renal failure or raised quick Sequential Organ Failure Assessment (qSOFA) score), admission to a high-care unit, leucopenia and leucocytosis, presence of intrathoracic fluid collections (drained and/or undrained), defect circumference at least 25 per cent, and overall conduit ischaemia/necrosis. AL after transhiatal oesophagectomy and a diet consisting of water only (versus nil by mouth, liquid or unrestricted diet) at diagnosis were associated with reduced 90-day mortality. Anastomotic reinforcement (omental wrap/pleural flap), nasogastric tube at diagnosis, and C-reactive protein (CRP) levels at diagnosis were not identified as leak-related prognostic factors.

SEAL score development and internal validation

The SEAL score was developed by including all 12 identified prognostic leak-related parameters in a multivariable logistic regression model (Table 4). After internal validation, the c-index for the SEAL score was 0.77 (95 per cent c.i. 0.73 to 0.81) and the SEAL score showed good calibration (Fig. 1).

Outcomes for patients in different AL severity classes according to the SEAL score are summarized in Table 5, including an example of a patient in each class. The majority of patients (51.2 per cent) were classified as having a moderate AL; 25.4 per cent had mild, 13.4 per cent severe, and 10.1 per cent had critical leak. There was good alignment between the observed and predicted mortality rate within each leak severity class. Patients with greater leak severity had a statistically significantly longer duration of hospital (and ICU) stay, longer time to leak healing, higher mortality rate (in-hospital, 30-day, 90-day, and 180-day mortality), and higher CCI score. Furthermore, the percentage of ECCG type I leaks declined, whereas the percentage of ECCG type III leaks increased. Model performance was good among 1401 patients treated in European centres, but could not be assessed accurately in 108 patients treated in non-European centres owing to the limited number of patients (Fig. S2).

The internally validated SEAL score was incorporated into an online application, which enables determination of leak severity and is available at https://www.tentaclestudy.com/seal-score.

Discussion

The SEAL score classifies patients with AL into four classes of leak severity according to the predicted risk of 90-day mortality. The score combines 12 leak-related prognostic factors at diagnosis, and showed good performance after internal validation. A more severe leak according to the SEAL score was associated with a longer duration of hospital and ICU stay, longer healing time, higher CCI score, and higher ECCG grade, indicating that this score is relevant beyond 90-day mortality. This unique cohort enabled identification of prognostic factors, and development and internal validation of the SEAL score.

Some limitations should, however, be discussed. There is a risk of bias owing to patient selection, but the patients were consecutive and the data validated. Patients with subclinical AL may be under-represented as they may not have been identified during screening for eligible patients. Such patients may not require admission or treatment; this is not the targeted population for the SEAL score, and omission of these patients therefore has few consequences. A recent prospective international audit¹, which included all patients undergoing oesophagectomy, found an AL rate of 14.2 per cent, with an AL mortality rate similar to that in the present study, indicating comparability of cohorts.

Appropriate measures were taken to ensure data quality; meticulous data verification was performed to ensure uniform data collection and data quality validation showed good data accuracy, similar to other surgical studies^31–33. Multiple imputation was used to increase precision and avoid bias during the analysis²⁵. Still, the high rate of unavailable data on defect circumference reflects current diagnostic strategies and limited reporting of endoscopic findings. The prognostic impact of defect circumference and conduit condition underscores the importance of endoscopy as a diagnostic assessment, and detailed reporting of imaging assessments may further improve the data quality of future studies. Even though the SEAL score was developed in a large international cohort and was validated internally, it is unknown whether the findings can be generalized²⁹. Independent external validation of the SEAL score should be undertaken as model performance could not be assessed accurately in centres outside Europe. However, external validation requires an additional large and detailed data set, which is not currently available.

The study has identified an array of leak-related prognostic factors in patients with AL, highlighting the complex and multifactorial character of AL severity. The present findings have confirmed previous suggestions that defect circumference, intrathoracic fluid collections, and conduit condition have a high prognostic impact^1,15,17–19. Patients with a diet consisting of water only at diagnosis were found to have better outcomes. As drinking water may help limit contamination, these patients could be less prone to developing sepsis. Interestingly, although CRP may have an important role in diagnosing AL^34–36, the present findings indicated that CRP levels do not reflect AL severity at diagnosis. Contrary to popular belief, anastomotic reinforcement (omental wrap) was not found to reduce the severity of AL^37–40. Transhiatal oesophagectomy was identified as a favourable prognostic factor, and the risk of developing intrathoracic manifestations may indeed be lower as no transthoracic resection is performed^18,41,42. However, after transthoracic oesophagectomy no difference was found regarding outcomes of cervical and intrathoracic AL, supporting the recent ‘chute hypothesis’, proposing that thoracic dissection may increase the risk of intrathoracic manifestations in cervical AL^19,42,43.

The SEAL score adopts a novel approach to determining AL severity by combining leak-related prognostic factors at diagnosis of AL. A higher SEAL score was associated with higher ECCG leak type, and the SEAL score expresses explicitly at diagnosis what the ECCG classification indicates implicitly once treatment has been completed¹⁴. The applicability of the ECCG classification is limited in clinical practice, whereas the SEAL score may be used to determine the severity of AL for individual patients. Moreover, use of the SEAL score may unify understanding of the impact of AL on patients, and surgeons, gastroenterologists and other physicians may monitor patients with severe or critical AL more closely. In the future, the SEAL score may guide treatment decisions, but its role is yet to be established. For example, patients with a higher SEAL score may benefit from more aggressive (surgical) treatment. For research purposes, the ECCG classification and the SEAL score may be complementary; the ECCG classification may be used to standardize reporting of AL treatments, and the SEAL score to report leak severity. Moreover, previous studies^1,44 were unable to assess the efficacy of AL treatments owing to confounding bias, whereas the SEAL score can be used to adjust for leak severity and may consequently reduce bias.

Development of the SEAL score is the first step towards finding evidence for the optimal treatment of AL. Future analyses of TENTACLE—Esophagus will investigate the efficacy of leak treatment taking into account AL severity; assess the association between practice variation and outcomes; and aim to develop a prediction model incorporating the SEAL score and preoperative factors to accurately predict mortality risk based on patient characteristics and leak severity.

In conclusion, the SEAL score combines leak-related parameters at diagnosis and grades leak severity into four classes based on individual predictions of 90-day mortality; the score reflects morbidity in terms of duration of hospital (and ICU) stay, healing time, CCI score, and ECCG leak type. In clinical practice, the score is instrumental in determining the severity of AL at diagnosis and may guide clinical decision-making in the future. In research, the SEAL score may be used to report and adjust for the severity of AL after oesophagectomy.

Collaborators

TENTACLE—Esophagus Collaborative Group: E. Matthée, C. A. M. Slootmans, G. Ultee, J. Schouten (Radboud university medical centre, Nijmegen, The Netherlands); S. S. Gisbertz, W. J. Eshuis, M. C. Kalff, M. L. Feenstra (Amsterdam UMC, University of Amsterdam, Cancer Centre Amsterdam, Amsterdam, The Netherlands); D. L. van der Peet, W. T. Stam (AmsterdamUMC, location VUmc, Amsterdam, The Netherlands); B. van Etten, F. Poelmann, N. Vuurberg, J. W. van den Berg (University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands); I. S. Martijnse, R. M. Matthijsen (Elisabeth-Tweesteden Ziekenhuis, Tilburg, The Netherlands); M. Luyer, W. Curvers, T. Nieuwenhuijzen (Catharina Ziekenhuis Eindhoven, Eindhoven, The Netherlands); A.k E. Taselaar (Erasmus medical centre, Rotterdam, The Netherlands); E. A. Kouwenhoven, M. Lubbers (Ziekenhuisgroep Twente, Almelo, The Netherlands); M. Sosef, F. Lecot, T. C. M. Geraedts (Zuyderland Medisch Centrum, Heerlen, The Netherlands); S. van Esser, J. W. T. Dekker (Reinier de Graaf Gasthuis, Delft, The Netherlands); F. van den Wildenberg (Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands); W. Kelder, M. Lubbers, P. C. Baas, J. W. A. de Haas (Martini Ziekenhuis, Groningen, The Netherlands); H. H. Hartgrink, R. R. Bahadoer (Leiden University Medical Centre, Leiden, The Netherlands); J. W. van Sandick, K. J. Hartemink, X. Veenhof (Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands); H. Stockmann, B. Gorgec, P. Weeder (Spaarne Gasthuis, Haarlem, The Netherlands); M. J. Wiezer, C. M .S. Genders (St. Antonius Ziekenhuis, Nieuwegein, The Netherlands); E. Belt, B. Blomberg (Albert Schweitzer, Dordrecht, The Netherlands); P. van Duijvendijk, L. Claassen, D. Reetz (Gelre, Apeldoorn, The Netherlands); P. Steenvoorde, W. Mastboom, H. J. Klein Ganseij (Medisch Spectrum Twente, Enschede, The Netherlands); A. D. van Dalsen, A. Joldersma, M. Zwakman (Isala, Zwolle, The Netherlands); R. P. R. Groenendijk, M. Montazeri (IJsselland Ziekenhuis, Cappelle aan de Ijssel, The Netherlands); St. Mercer, B. Knight, G. van Boxel (Portsmouth Hospital University Trust, Portsmouth, United Kingdom); R. J. McGregor, R. J. E. Skipworth, C. Frattini, A. Bradley (University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom); M. Nilsson, M. Hayami, B. Huang (Karolinska University Hospital, Stockholm, Sweden); J. Bundred, R. Evans (Queen Elizabeth Hospital, Birmingham, United Kingdom); P. P. Grimminger, P. C. van der Sluis, U. Eren (University Medical Centre Mainz, Mainz, Germany); J. Saunders, E. Theophilidou, Z. Khanzada (Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom); J. A. Elliott, J. Ponten, S. King, J. V. Reynolds (Trinity St. James's Cancer Institute, Dublin, Ireland); B. Sgromo, K. Akbari, S. Shalaby (Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom); C. A Gutschow, H. Schmidt, D. Vetter (University Hospital Zurich, Zurich, Switzerland); K. Moorthy, M. A. H. Ibrahim, G. Christodoulidis (Imperial, London, United Kingdom); J. V. Räsänen, J. Kauppi, H. Söderström (Helsinki University Hospital, Helsinki University, Helsinki, Finland); D. K. Manatakis, D. P. Korkolis, D. Balalis, A. Rompu (Saint Savvas Cancer Hospital, Athens, Greece); B. Alkhaffaf, M. Alasmar, M. Arebi (Salford Royal NHS Foundation Trust, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom); G. Piessen, F. Nuytens, S. Degisors (University Lille, Claude Huriez University Hospital, CHU de Lille, Lille, France); A. Ahmed, A. Boddy, S. Gandhi, O. Fashina (University of Leicester, Leicester, United Kingdom); E. Van Daele, P. Pattyn (Ghent University Hospital, Ghent, Belgium); W. B. Robb, M. Arumugasamy, M. Al Azzawi, J. Whooley (Beaumont Hospital, Dublin, Ireland); E. Colak, E. Aybar, A. C. Sari, M. S. Uyanik, A. B. Ciftci (Samsun Training and Research Hospital, Samsun, Turkey); R. Sayyed, B. Ayub, G. Murtaza, A. Saeed, P. Ramesh (Patel Hospital, Karachi, Pakistan); A. Charalabopoulos, T. Liakakos, D. Schizas, E. Baili, A. Kapelouzou (Laiko General Hospital, Athens, Greece); M. Valmasoni, E. S. Pierobon, G. Capovilla, S. Merigliano (University Hospital of Padova, Padova, Italy); C. Silviu, B. Rodica, A. Florin, R. Cristian Gelu, H. Petre (Sf. Maria Hospital, Bucharest, Romania); R. Guevara Castro, A. F. Salcedo (Clinica Universitaria Colombia, Bogota, Colombia); I. Negoi, V. M. Negoita, C. Ciubotaru, B. Stoica, S. Hostiuc (Carol Davila University of Medicine and Pharmacy Bucharest, Emergency Hospital of Bucharest, Bucharest, Romania); N. Colucci, S. P. Mönig, C. H. Wassmer, J. Meyer (Geneva University Hospitals, Geneva, Switzerland); F. R. Takeda, R. A. Aissar Sallum, U. Ribeiro, I. Cecconello (University of Sao Paulo, Sao Paulo, Brazil); E. Toledo, M. S. Trugeda, M. J. Fernández, C. Gil, S. Castanedo (Valdecilla Hospital, Santander, Spain); A. Isik, E. Kurnaz (Erzincan Binali Yildirim University, Erzincan, Turkey); J. F. Videira, M. Peyroteo, R. Canotilho (Instituto Português de Oncologica, Porto, Portugal); J. Weindelmayer, S. Giacopuzzi, C. A. De Pasqual (Verona University Hospital, Verona, Italy); M. Bruna, F. Mingol, J. Vaque, C. Pérez (La Fe Hospital, Valencia, Spain); A. W. Phillips, J. Chmelo, J. Brown, L. E. Han (Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom); J. A. Gossage, A. R. Davies, C. R. Baker, M. Kelly, M. Saad (Guy's and St Thomas' Hospitals, London, United Kingdom); D. Bernardi, L. Bonavina, E. Asti, C. Riva, R. Scaramuzzo (University of Milan, Milan, Italy); M. Elhadi, H. Abdelkarem Ahmed, A. Elhadi, F. A. Elnagar, A. A. A. Msherghi (Tripoli University Hospital, Tripoli, Libya); V. Wills, C. Campbell, M. Perez Cerdeira, S. Whiting (John Hunter New England LHD, Newcastle, Australia); N. Merrett, A. Das, C. Apostolou, A. Lorenzo (South Western Sydney Local Health District, Sydney, Australia); F. Sousa, J. Adelino Barbosa, V. Devezas, E. Barbosa, C. Fernandes (Centro Hospitalar Universitário São João, Oporto, Portugal); G. Smith, E. Y. Li, N. Bhimani, P. Chan, K. Kotecha (Royal North Shore Hospital, Sydney, Australia); M. W. Hii, S. M. Ward, M. Johnson, M. Read, L. Chong (St Vincent’s Hospital, Melbourne, Australia); M. J. Hollands, M. Allaway, A. Richardson, E. Johnston, A. Z. L. Chen (Westmead Hospital Hospital, Sydney, Australia); H. Kanhere, S. Prasad, P. McQuillan, T. Surman (Royal Adelaide Hospital, Adelaide, Australia); M. I. Trochsler, W. A. Schofield, S. K. Ahmed, J. L. Reid, M. C. Harris (The Queen Elizabeth Hospital, Adelaide, Australia); S. Gananadha, J. Farrant, N. Rodrigues, J. Fergusson (Canberra Hospital, Canberra, Australia); A. Hindmarsh, Z. Afzal, P. Safranek, V. Sujendran, S. Rooney (Addenbrooke’s hospital, Cambridge, United Kingdom); C. Loureiro, S. Leturio Fernández, I. Díez del Val (University Hospital Basurto, Bilbao, Spain); S. Jaunoo, L. Kennedy, A. Hussain (Brighton & Sussex University Hospitals, Brighton, United Kingdom); D. Theodorou, T. Triantafyllou, C. Theodoropoulos, T. Palyvou (Hippocration hospital, Athens, Greece); M. Elhadi, F. Abdullah Ben Taher, M. Ekheel, A. A. A. Msherghi (Sabratha National Cancer Institute, Sabratha, Libya).

Funding

The TENTACLE—Esophagus study received funding from Medtronic. The study was performed independently, and Medtronic had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript.

Acknowledgements

S.U. and M.V. contributed equally as first authors; F.v.W and C.R. contributed equally as senior authors. The authors thanks all those involved in the TENTACLE—Esophagus study for their contribution to this large international study. The TENTACLE—Esophagus study was registered in the Clinical Trials registry (NCT03829098) before the start of the study. Study data are not openly available. The authors are willing to share data upon reasonable request to the corresponding authors.

Disclosure. All authors declare funding from Medtronic for the submitted work. P.S. reports grants from The Enose Company, grants and other from Motus GI, grants from Pentax, grants from Micro-Tech, and other from Boston Scientific, outside the submitted work; B.K. reports grants from Medtronic and ZonMw, outside the submitted work; M.v.B.H. reports other from Mylan, other from Alesi Surgical, other from Johnson and Johnson, other from BBraun, other from Medtronic, grants from Olympus, and grants from Stryker, outside the submitted work; all fees unrelated to submitted work, paid to institution. The authors declare no other conflict of interest.

Supplementary material

Supplementary material is available at BJS online.

References

Author notes